The cuts at two Massachusetts plants follow further site closures and layoffs across the company over the past few years.

Despite recent evidence of its financial turnaround, Thermo Fisher’s layoff spree will continue into 2025. | Despite recent ...

OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Jefferies ...

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

To advance its gene-modified cell therapy to clinical stages, Captain T Cell will utilise the plasmid and viral vector ...

CDMO Rentschler Biopharma is signalling its intent to cut down cell and gene therapy operations by shutting down its UK ...

Viralgen and Axovia Therapeutics are set to form a partnership to progress the development and manufacturing of an adeno-associated virus vector serotype 9 (AAV9)-based gene therapy for retinal ...

The companies will work together by using the codon-optimized BBS1 AAV9 vector to minimize the vision loss caused by the ...

CAR T-cell therapies have established themselves as a frequently very successful and overall promising treatment option for various blood cancers for which no other effective therapies are available.

The companies will focus on advancing AXV-101, with which they hope to treat retinal dystrophy by targeting mutations in the BBS1 gene.